Keywords: Genzyme, Sanofi, Eliglustat, Gaucher disease, Ph II

Positive Ph II results for Genzyme’s oral Gaucher drug

Article | 09 February 2012

Print This

French drug major Sanofi’s (Euronext: SAN) US subsidiary Genzyme yesterday revealed four-year follow-up data from patients enrolled in ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in